Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies.
The effects of chitosan concentrations, osmolarity, medium and absorption enhancers in the chitosan solution on nasal insulin delivery were studied in vitro and in vivo. The penetration of insulin through the mucosa of rabbit nasal septum was investigated by measuring the transmucosal flux in vitro, while the nasal absorption of insulin in vivo was assessed by the efficiency in lowering the blood glucose levels in normal rats. It was demonstrated that increasing concentrations of chitosan up to 1.5% (w/v) caused an increase in the permeability of insulin across the nasal mucosa. Insulin given intranasally in hypo- or hyperosmotic formulation showed a higher hypoglycemic effect than insulin delivered in isoosmotic formulation. Insulin formulation in chitosan solution prepared with deionized water brought to a higher relative pharmacological bioavailability (Fr) value than that prepared with 50 mM pH 7.4 phosphate buffer. A formulation containing both 1% chitosan and 0.1% ethylenediaminetetraacetic acid (EDTA), 5% polysorbate 80 (Tween 80) or 1.2% beta-cyclodextrin (beta-CD) did not lead to a higher Fr than insulin formulated with 1% chitosan alone. The formulation containing both 5% hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and 1% chitosan was more effective at reducing blood glucose levels than the formulation containing 5% HP-beta-CD or 1% chitosan alone. The studies indicated that chitosan concentrations, osmolarity, medium and absorption enhancers in chitosan solution have significant effect on the insulin nasal delivery. The results of in vitro experiments were in good agreement with that of in vivo studies.
Yu
Shaoyun
S
Department of pharmaceutics, Health Science Center, Peking University, Beijing 100083, PR China.
Zhao
Ying
Y
Wu
Fenglan
F
Zhang
Xuan
X
Lü
Wanliang
W
Zhang
Hua
H
Zhang
Qiang
Q
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000281:Administration, Intranasal; D000818:Animals; D001682:Biological Availability; D001786:Blood Glucose / Q000187:drug effects; D048271:Chitosan / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004357:Drug Synergism; D004492:Edetic Acid / Q000737:chemistry; D005079:Excipients / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D049528:Insulin, Long-Acting / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics; D008297:Male; D009297:Nasal Mucosa / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009300:Nasal Septum / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009994:Osmolar Concentration; D010539:Permeability / Q000187:drug effects; D011136:Polysorbates / Q000737:chemistry; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012996:Solutions / Q000737:chemistry / Q000493:pharmacokinetics*; D014867:Water; D047392:beta-Cyclodextrins / Q000737:chemistry / Q000493:pharmacokinetics
D001786:Blood Glucose; D005079:Excipients; D049528:Insulin, Long-Acting; D011136:Polysorbates; D012996:Solutions; D047392:beta-Cyclodextrins; D014867:Water; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D048271:Chitosan; D004492:Edetic Acid